Neuralstem in the News
Drug might treat depression, brain damage in athletes
President and CEO Richard Garr is quoted in this comprehensive story on Neuralstem’s NSI-189/traumatic brain injury initiative with the National Football League Alumni Association.
Possible Brain Drug Test: NFL group, company hope to conduct new trial
In this trend segment on potential treatments for traumatic brain injury and PTSD, Jenna Lee interviews FOX News contributor, neurologist Dr. Matthew Fink, about Neuralstem’s new NSI-189/TBI initiative with the NFLAA.
NFL alumni take stance on front line of effort to treat brain injuries
Reporter Craig Wolff talks to former San Diego Charger Wayne Clark about Neuralstem’s and the National Football League Alumni Association’s new initiative to develop an NSI-189/traumatic brain injury trial for treating NFL alumni. “I’d be willing to participate in anything,” Clark said. “And I’d expect all of us, no matter our present condition, would do the same.”
NFL may test brain injury treatment on retired players
“When in doubt, sit it out.” CBS, reporting with AP, added to the Neuralstem-NFLAA NSI-189/TBI story citing the American Academy of Neurology researchers’ new guidelines that call for current athletes who have sustained a significant head injury during a game be removed from play.
NFL group, company teaming up for brain drug test
AP coverage of Neuralstem-National Football League Alumni Association initiative to develop a trial for treating NFL alumni members suffering from traumatic brain injuries with neurogenic NSI-189 was carried by numerous media outlets ranging from ABC News to The Washington Post.
- NFL Alumni Back New Drug to Keep Brain-Injuries From “Destroying Quality of Life”
- Drug which could reverse depression symptoms draws interest of NFL Alumni Association
- Neuralstem, NFL Alumni Association To Test Feasibility Of Traumatic Brain Injury Treatment
- Football and Concussions: New Drug To Be Tested on NFL Alumni
- Michigan University Joins Lou Gehrig’s Clinical Trial
Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.